Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vistra Corp (VST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Vistra Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Vistra Corp trades at $157.02 (market cap $53.56B). The key difference: Vistra Corp is the larger of the two by market cap, and Vistra Corp pays a 0.58% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | VST | |
|---|---|---|
Market Cap | $39.89B | $53.56B |
Sector | Health | Technology |
52-Week High | $491.22 | $217.92 |
52-Week Low | $278.09 | $134.71 |
Enterprise Value | $38.15B | $75.32B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Vistra Corp. (VST) trades at $158.86, up 0.56% today, with a bullish technical outlook supported by moving averages and a neutral RSI. The company reported strong Q1 2026 earnings beat but missed Q3 and Q4 2025 estimates. Revenue grew to $19.4B in 2026 with net profit margin improving to 11.52%. Recent news highlights AI-driven power demand and long-term PPAs with Meta and AWS as growth catalysts.
Outlook is positive with 91% analyst buy ratings and a $230.50 consensus price target, implying 45% upside. Risks include execution on growth initiatives and macroeconomic volatility. The stock offers exposure to rising electricity demand and stable cash flows from utility operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
